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ABSTRACT
Question Recent data suggest that anxiety disorders are as often comorbid with bipolar disorder (BD) as with unipolar depression; however, less
attention has been paid to comorbidity of anxiety disorders with BD. Generalised anxiety disorder (GAD) is one of the most prevalent anxiety
disorders that is highly comorbid with other mental disorders. We carried out a systematic review and meta-analysis to assess the degree of
comorbidity between GAD and BD.
Study selection and analysis We searched for all studies, which included primary data concerning the existence of GAD in patients with BD.
The literature search strategy, selection of publications and the reporting of results have been conducted with PRISMA guidelines. The meta-analysis
calculated prevalence estimates using the variance-stabilising Freeman-Tukey double arcsine transformation. We applied the inverse variance method
using both fixed-effects and random-effects models to estimate summary effects for all combined studies. Heterogeneity was assessed and
measured with Cochran’s Q and I2 statistics, respectively.
Findings The current meta-analysis analysed data from 28 independent studies and a total of 2975 patients from point prevalence studies and
4919 patients from lifetime studies. The overall random-effects point prevalence of GAD in patients with BD was 12.2% (95% CI 10.9% to 13.5%)
and the overall random-effects lifetime estimate was 15.1% (95% CI 9.7% to 21.5%). Both estimates reported significant heterogeneity (94.0% and
94.7%, respectively).
Conclusions Published studies report prevalence rates with high heterogeneity and consistently higher than those typically reported in the general
population. It is believed that comorbid GAD might be associated with a more severe BD course and increased suicidality, and it is unknown how
best to treat such conditions. The current meta-analysis confirms that GAD is highly prevalent in BD and the rate is higher in comparison to those in
the general population.
BACKGROUND
Comorbidity has been described as the presence of more than one dis-
order in a person in a defined period of time.1 Psychiatric comorbidity is
reported to be a common phenomenon in patients with bipolar disorder
(BD). The rates of lifetime comorbidity in BD seem to be higher than
50%2 3 and may reach even 70%.4–8 Taking into account the existing
substantial overlap between the symptoms of acute BD and those from
other mental disorders, it is recommended to diagnose a comorbid
mental disorder only if it occurs before the onset of bipolar illness or
during periods when mood symptoms are not prominent.9 10 This is
especially important concerning anxiety disorders which share many
symptoms with mood disorders and often put the question whether it
is high comorbidity or different facets of the same spectrum of disor-
ders. It is estimated that anxiety disorders are the most frequent disor-
ders in the general population.11 In various studies, generalised anxiety
disorder (GAD) comorbid with another mental disorder has been
reported at rates equal to 7–32%.12 Until two decades ago, most
research had focused on the comorbidity between unipolar depression
and anxiety disorders. Less attention has been paid to comorbidity of
anxiety disorders with BD.
There is convincing evidence that the rates of anxiety disorders are
higher among patients with BD compared with their rates in the
general population.7 Recent data suggest that anxiety disorders are as
often comorbid with BD as with unipolar depression.13 Clinically, it is
crucial to identify and treat comorbid anxiety disorders because of their
contribution to poor treatment response and recovery, fewer periods of
euthymia and higher rates of substance abuse and suicide
attempts.12 14–16 It is also important to define the comorbidity rate of
anxiety disorders in patients with BD because the treatment of this
comorbid condition is not straightforward and puts the patient at a high
risk to a number of adverse events including higher risk to
medication-induced switch.
OBJECTIVE
The aim of the current study was to systematically review the literature
for data concerning the comorbidity of GAD and BD. We conducted a
meta-analysis of the data retrieved so as to arrive at point and lifetime
rates of comorbidity.
STUDY SELECTION AND ANALYSIS
Review of the literature
Two authors (KNF and JV) developed the search code investigating the
comorbidity of GAD with BD with searches in PubMed/MEDLINE, from
inception until 6 June 2015.
One reviewer (KNF) screened the titles and abstracts resulting from the
search strategy, while a second reviewer ( JV) verified. When the inclu-
sion of a study was unclear, the full-text article was screened. This
review followed the recommendations of the Preferred Items for
Reporting of Systematic Reviews and Meta-Analyses (PRISMA) state-
ment.17 A checklist concerning the PRISMA procedure is included in
the online supplementary appendix.
Literature search key words
The PubMed database was searched using a combination of search
terms as follows:
“bipolar[All Fields] OR (“bipolar disorder”[MeSH Terms] OR
(“bipolar”[All Fields] AND “disorder”[All Fields]) OR “bipolar
























disorder”[All Fields] OR “mania”[All Fields]) OR (“bipolar
disorder”[MeSH Terms] OR (“bipolar”[All Fields] AND “disorder”[All
Fields]) OR “bipolar disorder”[All Fields] OR “manic”[All Fields]) AND
(generalized[All Fields] AND (“anxiety disorders”[MeSH Terms] OR
(“anxiety”[All Fields] AND “disorders”[All Fields]) OR “anxiety
disorders”[All Fields] OR (“anxiety”[All Fields] AND “disorder”[All
Fields]) OR “anxiety disorder”[All Fields])) OR GAD[All Fields].” Also,
the reference lists of books and reviews were scanned.18–20
Criteria for study selection
▸ English language
▸ Studies which included primary data concerning the existence of
GAD in patients with BD
Meta-analysis
Data abstraction and quality assessment
Two authors ( JV and KNF) used a standardised coding system previ-
ously pilot tested to extract the following data from the articles:
authors’ names, publication year, location, sample size, criteria for diag-
nosis, procedure for diagnosis (whether this was conducted by standar-
dised interview, semistandardised interview or clinical decision), number
of cases with BD, number of cases with GAD, number of cases with
any other diagnostic group which had been used as comparison.
Relevant data from each study were abstracted by one reviewer (KNF)
and verified by a second reviewer ( JV). Discrepancies in scoring were
resolved through discussion.
Data synthesis and implementation
Prevalence estimates were calculated using the variance-stabilising
Freeman-Tukey double arcsine transformation.21 The double arcsine
transformation is known to outperform other proposed methods of
prevalence estimates.22
We applied the inverse variance method using both fixed-effects and
random-effects models to estimate summary effects for all combined
studies. It has been shown that the inverse-variance weight in
fixed-effects meta-analysis is suboptimal when dealing with data with
low prevalence.23 In each meta-analysis, we synthesised the prevalence
estimates using the double arcsine transformation, and then we back-
transformed the pooled estimate to a proportion, so as to have an inter-
pretable scale. In the random-effects model, we estimated the hetero-
geneity variance among studies using the empirical Bayes estimator,24
also known as the Paule-Mandel estimator,25 and its 95% CI using the
Q-Profile method.26 Under the random-effects model, we also used the
Knapp and Hartung27 method as an alternative to infer about the
summary effect. The method estimates the uncertainty for the overall
treatment effect based on the t-distribution (with ‘number of studies-1’
degrees of freedom) and a weighted extension of the inverse variance
formula accounting for the between-study heterogeneity. Heterogeneity
was assessed with Cochran’s Q and I2 statistics.28 A low p value (ie,
p<0.10) of the Q statistic that variation in the study-specific effect
estimates is due to heterogeneity beyond chance. For I2, values
between 0% and 40% might not be important; 30–60% may represent
moderate heterogeneity; 50–90% may represent substantial heterogen-
eity and 75–100% may represent considerable heterogeneity.29
We presented fixed-effects and random-effects summary estimates
along with a corresponding 95% CI for each analysis in forest plots.
Differences between fixed-effects and random-effects estimates
suggest that there are differences between the point estimates from
smaller and larger studies: such differences were examined in out-
comes with 10 or more studies using funnel plots and Egger’s30 and
Begg’s regression test.31
The Baujat plot was used to detect the contribution of each study to
the overall heterogeneity.32 The Baujat plot reports on the x-axis the
contribution of each study to the overall heterogeneity, while on the
y-axis is reported the influence of each study on the overall treatment
effect, calculated as the standardised difference of the overall treatment
effect with and without each study. To control for adequacy of the
models and the identification of outliers, we used the radial plot33 34
and the standardised residuals plot35 in relation to the random-effects
model. For a random-effects model, the radial plot shows the sampling
variance of the observed effect size or outcome against the amount of
heterogeneity as estimated based on the model. As far as the standar-
dised residuals plot is concerned, if a study fits the model, its standar-
dised residual follows (asymptotically) a standard normal distribution. A
large standardised residual (>2 SD) for a study therefore may suggest
that the study does not fit the assumed model (ie, it may be an
outlier). When possible, differences in prevalence according to
characteristics of individuals or of studies were estimated by comparing
prevalence between subgroups of studies. We used metaregression
techniques to evaluate the impact of clinical variables: gender ratio,
mean age of the sample, diagnostic procedure. Subgroup analysis was
applied to estimate the impact of study characteristics: subtypes of BD,
on prevalence rates of generalised anxiety.
Meta-analysis was carried out with the ‘meta’ package36 and the
‘metafor’ package35 running in R V.3.0.2.37
FINDINGS
The initial MEDLINE search retrieved 1300 articles, whereas another 14
papers were identified from other sources. Eventually 30 papers were
eligible (7 studies from the MEDLINE search and 23 from other
sources). Fifteen of them included data with cross sectional preva-
lence.6 12 38–50 However the Simon et al studies12 49 50 include up to
the first 500 patients from the STEP-BD study while the Otto et al46
includes the first 1000 patients from the same study. Therefore in the
current analysis only the Otto et al.46 study was utilized. Thus 13
studies were eligible for the analysis for point prevalence.6 12 38–48 One
of the Simon et al studies12 was used only to calculate the comorbidity
rates separately for BD-I and BD-II patients. Another 19 papers con-
tained data concerning the lifetime prevalence2 6 12–14 16 47 48 51–61
and were included in the analysis. However, the Rihmer et al., 200158
reported data that also were reported in Szadoczky et al., 1998,60 and
data from Rihmer et al., 200158 was used only to calculate the
comorbidity rates separately for BD-I and BD-II patients. Overall data
from 28 independent studies were used in total. The PRISMA flowchart
is shown in figure 1 in the main manuscript. In detail the PRISMA flow-
chart is shown in figure 1 while a list of the studies used for the
analysis can be found in the web appendix. Sample sizes varied widely
across studies (N=20–918 in studies with point prevalence estimates;
24–1411 in studies with lifetime estimates) and females were over-
represented. The mean age was 37 (range 30–43) in point prevalence
studies and 38.9 (range 30–44) in lifetime studies (figure 2). In studies
with point prevalence estimates, the Structured Clinical Interview for
Diagnostic and Statistical Manual of Mental Disorders (DSM)—SCID
was applied in 12 studies to derive the diagnosis, and just one applied
the Schedule for Affective Disorders and Schizophrenia—Lifetime
version (SADS-L; table 1). In studies with lifetime estimates, the SCID
was applied in 10 studies, while 9 studies applied other standardised
procedures to draw the diagnosis (see table 2).
The fixed-effects point prevalence estimate of GAD in patients diag-
nosed with BD was 9.6% (95% CI 8.5% to 10.7%). The overall
random-effects point prevalence estimate of GAD in patients diagnosed
with BD was 11.5% (95% CI 6.6% to 17.4%; figure 3). Heterogeneity
was substantial: I2=94.0% (95% CI 91.2% to 95.9%; table 3).
Reanalysis of data without one outlier study gave a fixed-effects point
prevalence estimate equal to 12.2% (10.9% to 13.5%), with no statis-
tically significant change in the random-effects estimates: 12.9% (8.2%
























Figure 1 The PRISMA flow chart.
Figure 2 Sample size of studies on the prevalence of generalised anxiety disorder in patients with bipolar disorder.




































Bellani et al38 University of Texas Health Science Center at
San Antonio, USA
BD DSM-IV SCID 205 29.3 36.6±11.5 28 (13.7) Similar rates of depressive episodes between study groups
MDD 105 29.5 38.0±13.1 4 (3.8)
Boylan et al39 McMaster Regional Mood Disorders Program
(Hamilton, Ontario, Canada
BD DSM-IV SCID 138 31.9 ∼41* 43 (31.2) Outpatients, 70.3% BD-I, 29.7% rapid cycling
Chang et al40 National Cheng Kung University Hospital and
Tri-Service General Hospital, Taiwan
BD-I DSM-IV-TR SADS-L 120 48.33 31.4±11.5 10 (8.33) Outpatients from the Han population of Taiwan
BD-II 205 49.27 33.0±12.0 29 (14.14)
Cosoff and Hafner41 Adelaide, Australia BD DSM-III-R SCID 20 60 34.8±10 2 (10.0)
Schiz 60 7 (11.7)
Schizoaff 20 2 (10.0
Dell’Osso et al42 University Department of Psychiatry of Milan,
Italy
BD DSM-IV SCID 508 44.1 >40* 7 (1.4) 56.7% BD-I, 76.1% without any substance or alcohol abuse
Kauer-Sant’Anna
et al43
Bipolar Disorders Program of the University
Hospital at the Federal University, Porto Alegre,
Brazil
BD DSM-IV-TR SCID 162 33.95 >42* 19 (11.7) Outpatients of University hospital
Koyuncu et al44 Mood Disorders Unit of Psychiatry Department
of Istanbul Faculty of Medicine, Istanbul
University, Turkey
BD DSM-IV SCID 70 35.7 36.2±15.9 4 (5.71) Outpatients of University hospital
Mantere et al45 Mood Disorders Research Unit, NPHI, Helsinki,
Finland
BD DSM-IV SCID 191 47.1 37.7±12.2 29 (15.18) Acute phase BD, 47.1% BD-I, inpatients or outpatients. rapid cycling in
32.5%, and psychotic symptoms in 16.2% of patientsMDD 269 26.8 NA 37 (13.75)
McElroy et al6 Multisite USA and the Netherlands BD DSM-IV SCID 288 44.0 42.8±11.3 8 (2.78) STANLEY foundation data
Simon et al12 Multisite USA BD-I DSM-IV SCID 360 40.6 41.7±12.8 46 (12.8) First 500 patients of STEP-BD
BD-II 115 12 (10.4)




Cucurova University Adana, Turkey BD-I DSM-IV SCID 70 41.4 33.4±10.3 9 (12.9) Included only patients with BD-I
Zutshi et al48 NIMHANS, Bangalore, India BD DSM-IV SCID 80 71.3 30.06
±7.77
19 (23.8) Patients with remitted BD; the controls were relatives of neurological
patients
Controls 50 76.0 31.44
±7.85
3 (6)
Overall BD DSM (III-R or
IV)
SCID but 1 2975† 12.9 BD and MD rates are after meta-analysis. Corrected prevalence of GAD in
controls is 3% and in schizophrenia and schizoaffective is approximately






†The patients from the Simon et al12 study were not included because they overlap with those of the Otto et al46 study.
‡Estimation not directly supported by the data.
BD, bipolar disorder; DSM, Diagnostic and Statistical Manual of Mental Disorders; GAD, generalised anxiety disorder; N, sample size; NA, not available; MDD, major depressive disorder; SADS-L, Schedule for Affective Disorders and
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Azorin et al51 19 centres in France BD-I DSM-IV SCID 1090 42.0 43.0±14.0 217 (19.9) Acutely manic hospitalised patients with BD-I
Coryell et al14 5 academic centres, USA BD RDC SADS, LIFE 427 41.9 36.3±NA 20 (4.68) Prospective follow-up of 17.4±8.4 years
Goldstein and
Levitt52
National Institute on Alcoholism and Alcohol Abuse, USA BD-I DSM-IV NESARC 1411 41.0 38.9±NA 346 (24.5) 2001–2002 National Epidemiologic Survey,
USA
Grabski et al53 Three outpatient settings, Krakow Poland BD-I DSM-IV CIDI 50 42.5 44.6±11.0 17 (34.0) Outpatients in remission
BD-II 23 6 (26.1)
Kessler et al2 US epidemiological study BD-I DSM-III-R CIDI 29 58.6 NA 12 (41.4) National Comorbidity Study
McElroy et al6 Multisite USA and the Netherlands BD DSM-IV SCID 288 44.0 42.8±11.3 8 (2.8) STANLEY foundation data
Mantere et al54 National Public Health Institute, Helsinki, and Department of
Psychiatry, Jorvi Hospital, HUCH, Espoo, Finland
BD DSM-IV SCID 161 49.3 18–59 18 (11.2) Jorvi Bipolar Study




General Hospital of the Federal University of Bahia, Brazil BD DSM-IV SCID 62 20.9 42.0±12.73 8 (12.9) Mostly BD-I
Pini et al57 Pisa, Italy BD DSM-III-R SCID 24 45.4 37.9±12.0 8 (33.3) Depressed patients
MDD 38 25.0 47.0±15.0 14 (36.8)
Dysthymia 25 37.5 43.0±12.0 16 (64.0)
Rihmer et al58 Hungarian epidemiological study BD-I DSM-III-R DIS 95 NA 18–64 10 (10.5)
BD-II 24 5 (20.8)
MDD 443 62 (14.0)
Simon et al12 Multisite USA BD-I DSM-IV SCID 360 40.6 41.7±12.8 68 (18.9) First 500 patients of STEP-BD
BD-II 115 19 (16.5)
Slama et al59 Paris and Bordeaux, France BD DSM-IV DIGS 180 NA NA 7 (3.9) Patients in remission
Szadoczky et al60 Hungarian epidemiological study BD DSM-III-R DIS 149 44.0 18–64 22 (14.4) Epidemiological, rates weighted for sex
MDD 443 62 (14.0)
Tamam and
Ozpoyraz47
Cucurova University Adana, Turkey BD-I DSM-IV SCID 70 41.4 33.4±10.3 10 (14.3) Included only patients with BD-I
Tsai et al61 Taiwan BD-I DSM-IV CIDI 306 48.0 37.07±12.3 37 (12.1)
Yerevanian et al13 Los Angeles, USA BD DSM-III SCID, chart
review
35 51.4 ∼40 3 (8.6) Mostly BD-II
MDD 98 28.6 22 (22.5)
Young et al16 Clarke Institute of Psychiatry, Toronto, Canada BD RDC SADS 81 39.5 37.6 (19–66) 26 (32.1)
Zutshi et al48 NIMHANS, Bangalore, India BD DSM-IV SCID 80 71.3 30.06±7.77 20 (25) Patients with remitted BD; the controls were
relatives of neurological patientsControls 50 76.0 31.44±7.85 3 (6)








*Estimation not directly supported by the data.
BD, bipolar disorder; CIDI, Composite International Diagnostic Interview; DIGS, Diagnostic Interview for Genetic Studies; DIS, Diagnostic Interview Schedule; DSM, Diagnostic and Statistical Manual of Mental Disorders; GAD, generalised anxiety
disorder; HUCH, Helsinki University Central Hospital; MDD, major depressive disorder; N, sample size; NA, not available; NESARC, National Epidemiologic Survey on Alcohol and Related Conditions; RDC, Research Diagnostic Criteria; SADS,
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to 18.6%). This later value should be considered to be the most appro-
priate to consider as the cross-sectional estimate. The fixed-effects life-
time estimate of GAD in patients diagnosed with BD was 15.8% (95%
CI 14.8% to 16.9%). The overall random-effects lifetime estimate of
GAD in patients diagnosed with BD was 15.1% (95% CI 9.7% to
21.5%). Again, lifetime prevalence of GAD varied across studies,
depending on the characteristics of the samples (figure 4).
Heterogeneity was substantial: I2=94.7% (95% CI 92.8% to 96.0%).
The results suggest that the random-effects model was more appropri-
ate for this data set. There was a trend for samples with BD type I to
have a higher lifetime prevalence of GAD, while samples with BD type
II had a trend for a lower lifetime prevalence of GAD (20.1% vs 12.5%,
table 3).
DISCUSSION
Although the literature is somewhat consistent concerning the overall
high rates of comorbidity in patients with BD, it is inconclusive concern-
ing the rates of specific comorbid disorders. Methodological issues
include the characteristics of the population being studied and the
method of assessment. Epidemiological studies in the general popula-
tion often use trained lay interviewers while clinical studies often use
only highly experienced researchers. Thus, clinical samples are more
reliably evaluated, but they might include patients with a more severe
form of the illness. In contrast, general population samples have prob-
lematic assessment, which is done almost always with the use of
structured interviews. This often leads to an artificial inflation of rates,
because of false allocation or multiple allocation of the same
symptom.18 However, some authors argue that population-based
studies provide a better estimation of comorbidity rates compared with
studies carried out in primary and secondary care settings, because the
latter strategy introduces the bias of treatment-seeking into the
sample.7 The current meta-analysis used data from 28 independent
studies corresponding to a total of 2975 patients from point prevalence
studies and 4919 patients from lifetime studies. It reports that the
most probable point prevalence of GAD in patients with BD is 12.9%
(irrespective of BD type), while the lifetime prevalence is 20.1% in
patients with BD-I and 12.5% in patients with BD-II.
It is worth noting that in most studies point prevalence was a 12-
month prevalence and, because GAD is a chronic and relapsing dis-
order, this is probably the reason why point and lifetime prevalence
resulted to be very close to each other in our analysis. In some
instances, ‘point’ prevalence was higher than ‘lifetime’ prevalence as a
result of different methodology, different quality of study samples and
bias in the retrieval of information concerning past symptomatology.
Figure 3 Point prevalence of generalised anxiety disorder (GAD) in patients with bipolar disorder−W=individual study weight in both models.
Table 3 Effect sizes in meta-analysis of studies on GAD in BD
k n Prevalence 95% CI Q p Value I2 (%) 95%CI
Point studies FE model 12 2975 9.6% 8.5% to 10.7%
RE model 12 2975 11.5% 6.6% to 17.4% 182.1 <0.001 94.0% 91.2% to 95.9%
RE model without outliers 11 2467 12.9% 8.2% to 18.6% 84.1 <0.001 88.1% 80.7% to 92.7%
RE in subgroup analysis 1 11 2785 11.6% 6.2% to 18.3% 183.4 <0.001 94.5% 92.0% to 96.3%
RE in subgroup analysis 2 12 2212 11.1% 6.2% to 17.1% 170.1 <0.001 93.5% 90.5% to 95.6%
Subgroup analysis 1: without Simon et al12 and Taman and Ozpoyraz40
Subgroup analysis 2: with BD-I subsample in Simon et al12 and without BD-II subsample in Simon et al,12 BD-II subsample in Chang et al (2012) and Otto et al (2006)
Lifetime studies FE model 18 4919 15.8% 14.8% to 16.9%
RE model 18 4919 15.1% 9.7% to 21.5% 318.3 <0.001 94.7% 92.8% to 96.0%
RE in subgroup analysis 1 8 3411 20.1% 12.7% to 28.7% 48.8 <0.001 85.7% 73.7% to 92.2%
RE in subgroup analysis 2 13 1616 12.5% 6.4% to 20.1% 122.3 <0.001 90.2% 85.1% to 93.6%
RE in subgroup analysis 3 11 1603 11.2% 5.0% to 19.4% 110.8 <0.001 91.0% 85.9% to 94.2%
k=number of included studies
n=number of patients in the included studies
Subgroup analysis 1: with BD-I samples only
Subgroup analysis 2: with BD-II and mixed samples
Subgroup analysis 3: with mixed samples only
BD, bipolar disorder; FE, fixed-effects model; GAD, generalised anxiety disorders;
RE, random-effects model with Bayesian estimator.
























Published studies report prevalence rates with high heterogeneity;
however, these rates are consistently higher than those typically
reported in the general population. The rates vary across different study
populations. It is possible that patients regularly admitted to hospital
have higher rates of GAD than those treated primarily in the commu-
nity.41 In one such study,39 a higher than usual frequency of comorbid
in terms of point prevalence of GAD was reported. That study included
patients from a specialised mood clinic with a focus on refractory mood
disorders. The lowest rates of point prevalence of comorbid GAD were
found in a study from Italy and the rate reported was 1.4%42 while the
highest rate concerned lifetime prevalence, which came from a study
from the USA and was equal to 41.4%.2 The results of that study were
based on 29 cases of patients with BD-I alone, which leads to impreci-
sion in parameter estimates. Although it was a large general population-
based study with a total sample size of 8098, the problem was that
BD-I is rare in the general population, and this is why only 29 cases
with BD were identified. Since the population in this study consisted of
BD-I only, the generalisation of the findings to the whole group of
patients with BD is questionable. The literature regarding the stronger
association of GAD to specific BD types is inconsistent. In one study,
GAD was found to be more strongly associated with BD-II than BD-I,
with rates being 20.8% vs 10.5%, respectively.58 The major limiting
factor in this study was the patients’ recall bias of the history. Of
course, this is not a problem unique to that study. However, owing to
this bias, many patients with BD-II might be classified as unipolars and
therefore not included in such studies. In contrast, there are studies
reporting that GAD is more strongly associated with BD-I.12
GAD is found to be highly comorbid with other mental disorders. Major
depressive disorder (MDD) and GAD have the highest comorbidity rates
to each other of all other mood and anxiety disorders.62 In the National
Comorbidity Survey (NCS), 67% of individuals with GAD also reported
comorbid MDD, and 20% of individuals with MDD reported comorbid
GAD.63 In another study of 1127 outpatients, it was found that current
and lifetime anxiety and mood disorders are 57% and 81%, respect-
ively.62 High prevalence rates for anxiety disorder in people with psych-
osis are also reported, although the rates vary strikingly across the
studies. Pooled prevalence rates of cooccurrence of GAD in schizophre-
nia in 52 studies were 9.8% (4.3% to 15.4%).64 It is also reported that
over 30% of adults with obsessive-compulsive disorder have a lifetime
history of GAD.65 66
There is no clear consensus on the role of sociodemographic variables
on the comorbid prevalence of GAD in cases with BD, and often the
studies use a vague ‘anxiety’ variable rather than a precise GAD diag-
nostic category. In some studies, an association between female
gender47 67 68 or younger age39 was reported; however, negative
reports also exist.16 59 69 Some studies reported a relationship of
anxiety comorbidity with earlier age at onset of BD.6 12 39 69 70 This
may be due to the fact that sometimes anxiety disorders seem to
precede bipolar illness and therefore hasten its outbreak, whereas in
other cases they may occur afterwards. In contrast, there are studies
that do not find such a relationship.51
Comorbid GAD might be associated with a more severe BD course, more
past depressive episodes, less interepisode recovery and poorer response
to acute phase treatment, and a need for more numbers of mood stabili-
sers for acute management.71 The study of 135 patients with GAD with
or without other anxiety and mood disorders found that when GAD was
comorbid with any other disorder, the chance of remission was three
times less than when GAD was absent.72 Also, it has been reported that
an independent association of comorbid anxiety with greater severity and
impairment was demonstrated in patients with BD across all phases of
the illness.12 Anxiety has also been related to more severe illness in
another study, having important consequences regarding symptom-rated
and patient-rated outcomes.73–75 An association of the presence of
anxiety symptoms with greater severity of manic symptoms and longer
hospitalisations was demonstrated.76 Patients can experience work,
family, social impairment and increased healthcare costs and strains on
family support.73 Patients with BD with high anxiety levels tend to have a
greater proportion of weeks in major depressive episodes and a lesser
proportion of weeks in manic or hypomanic episodes.14 A relationship
between additional anxiety and depressive symptomatology was reported
in many of the previous studies.47 67 70 77 Current depression but not
mania could predict comorbid anxiety disorders and poorer treatment
response.67 Some authors report that the presence of anxiety is strongly
associated with higher impulsivity in mood disorders.38 78 79 Impulsivity
may relate differently to dangerous behaviours like suicidality and sub-
stance use in bipolar illness. This relationship may be responsible for the
higher number of suicide attempts found in the population of comorbid
anxiety in patients with BD.80
It is well known that comorbid GAD and BD are often treated with ben-
zodiazepines (BZDs) that have some benefits for patients with BD, but
Figure 4 Lifetime prevalence of generalised anxiety disorder (GAD) in patients with bipolar disorder−W=individual study weight in both models.
























they may also lead to or exacerbate substance abuse. The 5-year preva-
lence of BZD use among patients with BD with and without comorbid
substance use disorder was reported to be 75% and 58%, respect-
ively.81 Moreover, adjunctive BZD use at the time of symptom remission
has been linked with higher risk of mood episode recurrence, as com-
pared with no BZD use, in patients with BD-I and BD-II.82 However,
some studies report no significant effect of BZD use on any outcome
measure in patients with BD with comorbid anxiety or substance use
disorders.83 Furthermore, in some studies, BZDs are suggested as a
possible adjunctive therapy for extending follow-up and thus preventing
recurrence in patients with BD.84 On the other hand, the data are posi-
tive concerning the usefulness of quetiapine (50–600 mg/day),85–89 lur-
asidone (20–120 mg/day)90 and paroxetine (20 mg/day)89 but not
divalproex (500–3000 mg/day),88 risperidone (0.5–4 mg/day)91 or zipra-
sidone.92 Although approved for the treatment of GAD, gabapentine has
no data concerning the treatment of anxiety in patients with BD and
has negative data concerning its use against acute mania.93 94
One interesting and also important feature of this study is that only one-
quarter (7 out of 30) papers were identified through the MEDLINE
search while the rest were identified by the careful and laborious scan-
ning of reference lists of review papers and books. The reason for this
is not entirely clear, but at least partially it is because the data were
hidden in studies with different aims and scope; therefore, the key
words did not work. This leads to two inevitable conclusions: first, one
could not be sure that more such studies exist and remain to be identi-
fied, and second, the reliability and validity of review and meta-analytic
studies, including the current one, is problematic.
An important methodological limitation concerns the method most
studies used to diagnose comorbid disorders. Although a comorbid
anxiety disorder should only be diagnosed in BD if its symptoms occur
independently of mood symptoms, this was probably not the case in
most studies which probably used a simple DSM criteria approach. It is
important to note that in no DSM edition is there a requirement for
symptoms and diagnosis to be independent; therefore, in most
instances, it is highly likely that GAD symptoms overlapped with those
of BD.
In conclusion, this meta-analysis confirms that GAD is highly prevalent
in BD and the prevalence rates are higher than those reported in the
general population, but it also highlights the great variations in rates
among studies. Identifying and treating GAD can be clinically significant
in order to lessen BD severity, improve response to treatment of manic
or depressive symptoms and reduce suicidality.
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